Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021


HomeFUNDINGSynklino ApS Raises Seed Round to Develop Breakthrough Infection Treatment for Transplant Patients

Synklino ApS Raises Seed Round to Develop Breakthrough Infection Treatment for Transplant Patients

September 29, 2020

Synklino ApS, an emerging biotech company developing first-in-class breakthrough treatment to eliminate cytomegalovirus (CMV) infections in the transplant setting, today announces the successful closing of a seed financing led by Eir Ventures and Vaekstfonden.

Synklino ApS is a spinout from the University of Copenhagen and the Technical University of Denmark established to develop groundbreaking therapies against devastating viral infections. Synklino is incubated at the BioInnovation Institute in its prestigious Creation House program.

CMV is a virus that infects most people in adulthood and is the main agent involved in infectious complications following transplantation with major risk for morbidity, transplantation complications and increased hospital readmissions. Synklino’s drug candidate SYN002 has the unique potential to eliminate CMV from infected patients by targeting both lytic and latent infection.

Thomas Kledal, co-founder and CEO said: “Our goal is to provide patients a chance to live a full life after receiving a transplant. This financing will enable us to advance our lead program towards clinical testing, strengthen the management team and leverage the highly experienced venture and biotech expertise of Eir Ventures and Vaekstfonden, as we move to the next stage of growth.”

Stephan Christgau, Founding Partner of Eir Ventures, commented: “Synklino has developed a novel, first in class anti-viral therapy with the potential to be a game-changer offering the potential for CMV infection management. No other marketed or pipeline therapy has the potential to eliminate CMV infections in transplant patients. Synklino is a great example of Eir Venture’s strategy to back entrepreneurs in the Nordics developing highly innovative treatments for patients with underserved medical needs.”

Lene Gerlach, Investment Manager, Vaekstfonden, stated: “Vaekstfonden strongly supports spinout companies from Danish universities. Synklino is based on outstanding research performed by high-caliber researchers at the University of Copenhagen and the Danish Technical University. We see great potential in Synklino and its anti-viral drug candidate, which may revolutionize patient therapy and achieve higher standards of good health and well-being.”

John Haurum, Chairman of the Board, concluded: “Synklino’s technology is first-in-class and represents the new generation of anti-infectives that have the potential to make a significant impact in improving transplant patient care, an enormous poorly met medical need. I am looking forward to working with Thomas Kledal, CEO, who brings extensive drug development experience, which combined with the Company’s scientific foundations could lead to products that materially improve the options available to transplantation and infectious disease specialists and their patients.”

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy